Medistim ASASTU:MD1 -0.99%92 EBITDA Margin % is 28.83% as of Mar. 2026, which is 6% below its 10-year median of 30.68. GuruFocus rates STU:MD1 with a GF Score™ of 92/100 and a GF Value™ of €22.94. The stock has 1 warning sign investors should review. Among 816 Medical Devices & Instruments companies, Medistim ASA ranks better than 91.3% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medistim ASA's EBITDA for the
three
months ended in Mar. 2026 was €5.21 Mil. Medistim ASA's Revenue for the
three
months ended in Mar. 2026 was €18.06 Mil. Therefore, Medistim ASA's EBITDA margin for the quarter that ended in Mar. 2026 was 28.83%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medistim ASA EBITDA Margin % Related Terms
Medistim ASA EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Medistim ASA's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MD1 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Medistim ASA's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medistim ASA EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medistim ASA's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medistim ASA's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medistim ASA (STU:MD1) has a EBITDA Margin % of 28.83% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medistim ASA and its competitors. This is near median its historical median of 30.68. Over the past decade, Medistim ASA's EBITDA Margin % has ranged from 24.98 to 34.90. According to the industry distribution chart, Medistim ASA ranks #71 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 8.7%.
Is Medistim ASA's EBITDA Margin % too high?
Medistim ASA's current EBITDA Margin % of 28.83% is near median its 10-year median of 30.68. Over the past 10 years, this metric has ranged from a low of 24.98 to a high of 34.90. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Medistim ASA's value of 28.83% is 285.7% above this industry median. Based on the distribution chart, Medistim ASA ranks #71 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medistim ASA has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medistim ASA ranks #71 out of 816 companies for EBITDA Margin %. This places Medistim ASA in the top 9% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Medistim ASA's value of 28.83% is 285.7% above this benchmark. Historically, Medistim ASA's own EBITDA Margin % has ranged from 24.98 to 34.90 over the past decade. While the company's 10-year median is 30.68 vs. the industry median of 7.48, Medistim ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medistim ASA's current EBITDA Margin % of 28.83% is 285.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medistim ASA and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medistim ASA's current EBITDA Margin % is 28.83%, which is near median its own 10-year median of 30.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Medistim ASA (STU:MD1) has a current EBITDA Margin % of 28.83%. The stock's GF Value™ is €22.94, compared to a current price of €20.10 — trading 12.4% below its estimated fair value. The current EBITDA Margin % is 28.83%, which is near median its 10-year median of 30.68 and 285.7% above the Medical Devices & Instruments industry median of 7.48. Medistim ASA's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medistim ASA (STU:MD1), the current EBITDA Margin % is 28.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medistim ASA (STU:MD1) Overvalued in 2026?
Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued.
The current stock price of €20.10 is trading 12.4% below its estimated GF Value™ of €22.94.
Key valuation signals for STU:MD1:
EBITDA Margin %: 28.83% (near median its 10-year median of 30.68)
GF Value™: €22.94 vs. price of €20.10 (12.4% below fair value)
Industry Position: 285.7% above the Medical Devices & Instruments median (#71 of 816)
No single metric tells the full story. See the STU:MD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
92GF Score
Get the complete analysis for STU:MD1
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MD1 has been successfully added to your 
